(Q35753607)

10 August 2017

title

Genetic polymorphisms of cytochrome P450 enzymes and the effect on interindividual, pharmacokinetic variability in extensive metabolizers (English)

1 reference

10 August 2017

1 reference

Joseph D Ma

1

1 reference

10 August 2017

Anne N Nafziger

series ordinal

2

1 reference

10 August 2017

Joseph S Bertino

series ordinal

3

1 reference

10 August 2017

publication date

1 May 2004

1 reference

The Journal of Clinical Pharmacology

10 August 2017

published in

1 reference

10 August 2017

volume

44

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

447-456

1 reference

The genetic basis of variability in drug responses

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Genetic Aspects of Drug Disposition and Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Molecular basis of polymorphic drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Genetic polymorphisms in assessing interindividual variability in delivered dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Polymorphic hydroxylation of Debrisoquine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacogenetics and adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Genetic contribution to variable human CYP3A-mediated metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The major fluvoxamine metabolite in urine is formed by CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Cytochrome P450 3A: ontogeny and drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Advances in understanding drug metabolism and its contribution to variability in patient response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004264642

21 January 2018

Identifiers

DOI

10.1177/0091270004264642

1 reference

10 August 2017

1 reference